AC Immune SA (NASDAQ:ACIU) Short Interest Up 23.9% in March

AC Immune SA (NASDAQ:ACIU) was the recipient of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 1,350,000 shares, a growth of 23.9% from the February 28th total of 1,090,000 shares. Based on an average trading volume of 182,400 shares, the days-to-cover ratio is currently 7.4 days. Currently, 2.2% of the shares of the company are short sold.

Institutional Investors Weigh In On AC Immune

Hedge funds have recently modified their holdings of the business. Quinn Opportunity Partners LLC purchased a new position in AC Immune during the fourth quarter valued at $27,000. Two Sigma Advisers LP purchased a new stake in AC Immune in the fourth quarter worth about $36,000. Boothbay Fund Management LLC bought a new position in shares of AC Immune in the fourth quarter worth about $38,000. RPO LLC purchased a new position in shares of AC Immune during the 4th quarter valued at about $51,000. Finally, Jane Street Group LLC bought a new position in shares of AC Immune during the 4th quarter valued at approximately $66,000. Institutional investors own 51.36% of the company’s stock.

AC Immune Stock Up 4.7 %

AC Immune stock opened at $1.88 on Thursday. AC Immune has a 52-week low of $1.77 and a 52-week high of $4.98. The company has a market cap of $188.77 million, a P/E ratio of -4.09 and a beta of 1.49. The business has a 50-day simple moving average of $2.43 and a two-hundred day simple moving average of $2.88.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of AC Immune in a research report on Friday, March 14th.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.